Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,040.00
-10.00 (-0.17%)
At close: Sep 11, 2026

Sinil Pharmaceutical Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
10,1509,3134,6437,5194,9447,340
Short-Term Investments
30,67029,90029,07015,90018,41013,530
Cash & Short-Term Investments
40,92139,21433,71323,41923,35420,870
Cash Growth
14.62%16.31%43.96%0.28%11.90%43.01%
Accounts Receivable
20,67919,55120,24821,87823,42020,588
Other Receivables
507.14721.11590.8967.33293.28133.52
Receivables
21,18620,27220,83922,84523,71320,721
Inventory
26,13623,00922,86122,49220,18816,700
Prepaid Expenses
18.3427.7128.1827.4519.9224.67
Other Current Assets
408.5732.557.523.856.05110.3
Total Current Assets
88,67082,55577,44968,78767,28058,427
Property, Plant & Equipment
42,03842,64544,78941,91635,74430,999
Long-Term Investments
956.03882.43726.62839.01966.421,512
Other Intangible Assets
2,3242,3821,7361,8101,8701,801
Long-Term Accounts Receivable
-0----
Long-Term Deferred Tax Assets
3,0152,5692,4132,0971,9441,804
Other Long-Term Assets
38,13838,45538,69836,96034,97834,381
Total Assets
175,141169,489165,861152,460142,832128,974

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
6,0544,9135,3565,4556,8074,967
Accrued Expenses
1,9141,067897.02901.59824.11734.16
Current Portion of Leases
141.3143.94164.45165.01135.5133.75
Current Income Taxes Payable
909.25370.942,161267.592,105486.48
Other Current Liabilities
9,1058,1707,8757,3556,0885,702
Total Current Liabilities
18,14314,66516,45314,14515,95912,023
Long-Term Leases
86.19139.26268.23379.123.98139.48
Pension & Post-Retirement Benefits
2,6101,8822,3642,3942,5602,387
Other Long-Term Liabilities
470.72453.09270.53646.791,0311,228
Total Liabilities
21,31017,13919,35617,56519,55415,777

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
5,9935,9935,9935,9935,7715,609
Additional Paid-In Capital
1,1701,1701,1701,1701,1701,170
Retained Earnings
147,751146,269140,444128,688117,118106,663
Treasury Stock
-1,358-1,358-1,358-1,358-1,285-1,180
Comprehensive Income & Other
275275256.8402.28503.25934.27
Shareholders' Equity
153,832152,350146,506134,895123,277113,196
Total Liabilities & Equity
175,141169,489165,861152,460142,832128,974

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
227.49283.19432.68544.13139.48273.22
Net Cash (Debt)
40,69438,93133,28122,87523,21420,597
Net Cash Growth
15.14%16.98%45.49%-1.46%12.71%45.04%
Net Cash Per Share
-3367.832879.071978.432086.881832.18
Filing Date Shares Outstanding
-11.5611.5611.5611.1211.24
Total Common Shares Outstanding
-11.5611.5611.5611.1211.24
Working Capital
70,52767,89060,99654,64351,32146,403
Book Value Per Share
-13179.5312673.9911669.5611082.3210069.36
Tangible Book Value
151,507149,968144,769133,085121,407111,395
Tangible Book Value Per Share
-12973.4612523.7911512.9710914.209909.14
Land
2,0942,0942,0942,0942,0942,094
Buildings
38,55238,23936,45634,19328,42919,865
Machinery
54,73054,54750,58247,68017,6546,877
Construction In Progress
1,893167.43,0561254,9941,463